We report a case of neuromyelitis optica spectrum disorders (NMOSD), who developed after the pembrolizumab treatment, an immune checkpoint inhibitor, against lung adenocarcinoma. The present case is discussed with the lung adenocarcinoma specimen which was stained by aquaporin-4 (AQP4) and with literature review of NMOSD linked to immune checkpoint inhibitors.
A 62-year-old Japanese man presented with acute diencephalic syndrome, left optic neuritis, and myelitis 5 months after initiation of pembrolizumab treatment for lung adenocarcinoma. He was diagnosed with NMOSD based on serum anti-aquaporin-4 (AQP4) antibody positivity. Immunohistochemistry of lung biopsy samples showed AQP4 expression on CD68+ cells. This is the fifth reported case of AQP4+ NMOSD triggered by an immune checkpoint inhibitor and the first with a brain lesion. Four out of five NMOSD cases, including the present case and one case with lung metastasis, had lung cancer.
Immune checkpoint inhibitors may trigger AQP4+ NMOSD owing to their molecular similarity to AQP4 expressed in lung and glial tissues. Prompt brain/spinal cord imaging and anti-AQP4 antibody testing may facilitate early diagnosis of immune-mediated adverse event in central nervous system associated with immune checkpoint inhibitors.
Pembrolizumab, an inhibitor of programmed death 1 (PD-1), has applications in a wide range of advanced-stage malignancies, including non-small cell lung cancer (NSCLC). Pembrolizumab treatment enhances immunity against tumors and improves survival. It has recently replaced cytotoxic chemotherapy as a first-line therapy against advanced NSCLC lacking a driver mutation . However, PD-1 inhibitor treatment may induce immune-mediated adverse events, including neurological events such as headache, encephalopathy, meningitis, Guillain-Barré-like syndrome, myasthenic syndrome, and central nervous system demyelinating disorders .
Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory central nervous system demyelinating syndrome, which is usually associated with serum anti-aquaporin-4 (AQP4) antibody (AQP4+ NMOSD) . NMOSD core symptoms include optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy or acute diencephalic clinical syndrome, and symptomatic cerebral syndrome. Herein, we report a case of AQP4+ NMOSD induced by pembrolizumab treatment and compare it with previous reported cases.
A 62-year-old right-handed Japanese man with type 2 diabetes mellitus presented with an 8-month history of hoarseness. Chest computed tomography revealed a space-occupying lesion in the hilum and apex of the left lung, which extended into the upper mediastinum (64 mm in short-axis diameter). Aspiration biopsy confirmed the diagnosis of lung adenocarcinoma. Immunohistochemistry revealed that the lesion was thyroid transcription factor 1 (TTF-1) positive, napsin A equivocal, and p40 negative.
Brain magnetic resonance imaging (MRI) before chemotherapy initiation did not reveal any brain metastasis or other abnormality. The tumor was graded as T4N3M0, stage IIIC. Molecular profiling of the EGFR, ALK, ROS-1 genes revealed no sensitizing alterations. The anti-programmed death ligand 1 (PD-L1) tumor proportion score was < 1%.
Five months prior to neurological symptom onset, treatment with cisplatin 94 mg, pemetrexed 835 mg, and pembrolizumab 200 mg was initiated and repeated every 3 weeks for four courses, followed by four courses of pemetrexed 835 mg and pembrolizumab 200 mg treatment.
At the last pemetrexed and pembrolizumab treatment, the patient experienced difficulty walking and became wheelchair bound within 2 weeks. He developed somnolence, left hemiplegic ataxia, dysarthria, and dysesthesia in the right arm. Ophthalmological examination showed a visual acuity of 0.2 in the right eye and 0.3 in the left eye, left-side predominant bilateral upper gaze, and left abduction and down gaze palsy. Brain MRI showed a T2 high-signal lesion adjacent to the ventricle in the right thalamus and the right posterior limb of the internal capsule and the right cerebral peduncle, with edema and gadolinium enhancement (Fig. 1A–D). Cerebrospinal fluid examination revealed 7 cells/μL, protein 109 mg/dL, and glucose 130 mg/dL. Serum anti-Hu, Ri, CRMP5, Ma2, amphiphysin, VGKC, AQP4, and myelin oligodendrocyte glycoprotein (MOG) antibodies were tested before steroid therapy initiation, of which only anti-AQP4 antibody tested positive in a cell-based assay , which confirmed the diagnosis of NMOSD. Written consent was obtained. Spinal MRI showed a left anterior intraspinal cord bright spotty lesion at the T3 level, extending for the length of two vertebral segments (Fig. 1E, F).
Immunohistochemical staining of the lung biopsy sample showed that AQP4 and cluster of differentiation (CD)68 were co-expressed on cells in the adenocarcinoma lesion, indicating that macrophages inside the tissue expressed the AQP4 antigen (Fig. 2).
Chemotherapy, including pembrolizumab, was discontinued. Dexamethasone 6.6 mg/day treatment was initiated, maintained, and tapered. The gadolinium-enhanced lesion disappeared, leaving a necrotic focus in the right thalamus. Left critical flicker fusion frequency was diminished (37 Hz) and left central visual field sensitivity transiently decreased, with full recovery. Four months after the onset of neurological signs, the patient’s consciousness was clear with normal sensation, but his left eye palsy remained. He was able to stand alone and walk a few meters with assistance.
Discussions and conclusion
The diagnosis of NMOSD by the 2015 International Panel on neuromyelitis optica Diagnosis (IPND) was defined as, AQP4 antibody seropositive patients with only a single compatible syndrome (optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations) or AQP4 antibody seronegative patients, dissemination in space is necessary in addition to certain MRI requirements . To the best of our knowledge, four cases of AQP4+ NMOSD and a case of seronegative NMOSD induced by PD-1 inhibitor treatment have been reported until date (Table 1) [5,6,7,8,9]. Four of the six patients had lung cancer (including one lung metastasis), there were one case each of Hodgkin lymphoma, clear cell kidney cell carcinoma, and uveal melanoma. Four cases were induced by nivolumab treatment and two were induced by pembrolizumab. Their NMOSD symptoms started 2 weeks to 11 months after starting ICI treatment. Four patients presented with myelitis, one with optic neuritis, the present case being the first to present with brain lesion. Five patients showed partial recovery and one died.
A meta-analysis of central nervous system demyelinating disorders associated with immune checkpoint inhibitor (ICI) therapy published in 2018 revealed 23 cases, including seven of myelitis, five of multiple sclerosis, four of isolated optic neuritis, one of NMOSD,  and six of atypical demyelination . Nine cases of optic neuritis have been reported as adverse events after ICI induction .
The PD-1/PD-L1 pathway can inhibit self-reactive T cells and protect against autoimmunity via induction of regulatory T cells (Tregs) and direct inhibition of pathogenic self-reactive T cells. T-cell responses to AQP4 and Th17 deviation with decreased Treg count have been reported in patients with AQP4+ NMOSD . T-cell responses may play a role in the development of AQP4+ NMOSD after ICI.
Immunohistochemistry of the lung biopsy samples suggested that lung AQP4 antigen was scavenged by local CD68-positive macrophages, which may lead to antigen (AQP4) presentation. Notably, four of the five reported cases, including the present case, of AQP4+ NMOSD combined with neoplasm were associated with lung cancer [5, 6, 8]. Additionally, paraneoplastic NMOSD expressing AQP4 has been reported in a patient with lung adenocarcinoma . The amount of AQP4 in lung adenocarcinoma has been reported to be not significantly different  or even less  than the normal lung tissue. Therefore, it is not the amount of AQP4 on the tissue from lung cancer but the production of anti-AQP4 antibody induced by ICI may be critical for the patogenesis of NMOSD with lung cancer treated with ICI. ICI may trigger AQP4+ NMOSD owing to their molecular similarity to AQP4 expressed in lung and glial tissues.
It is unknown whether our patient wasanti-AQP4 antibody positive before chemotherapy initiation. This should be addressed in future studies. In this case, it is not possible to rule out the probability of a paraneoplastic syndrome, but the clinical course suggested that ICI treatment played an important role in disease induction.
In conclusion, we reported a patient with NMOSD who developed diencephalon clinical syndrome and optic neuritis with myelitis after pembrolizumab treatment for lung adenocarcinoma. This is the fifth reported case of AQP4+ NMOSD induced by treatment with a PD-1 inhibitor and the first with encephalitis. Although AQP4+ NMOSD as an immune-mediated adverse event of PD-1 inhibitor is rare, prompt brain/spinal cord imaging and anti-AQP4 antibody testing may facilitate early diagnosis.
Availability of data and materials
The datasets used and/or analysed during the current study are presented within the manuscript. Although, data may be available from the corresponding author on reasonable request.
Immune checkpoint inhibitor
Neuromyelitis optica spectrum disorders
Non-small cell lung cancer
Programmed death ligand-1
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.
Oliveira MCB, de Brito MH, Simabukuro MM. Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature. Front Neurol. 2020;11:538695. https://doi.org/10.3389/fneur.2020.538695.
Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, et al. The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. J Neuroimmunol. 2019;336:577021. https://doi.org/10.1016/j.jneuroim.2019.577021.
Narumi Y, Yoshida R, Minami Y, Yamamoto Y, Takeguchi S, Kano K, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018;18 1:95. https://doi.org/10.1186/s12885-018-3997-2.
Shimada T, Hoshino Y, Tsunemi T, Hattori A, Nakagawa E, Yokoyama K, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord. 2020;37:101447. https://doi.org/10.1016/j.msard.2019.101447.
Nasralla S, Abboud H. Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events. Mult Scler Relat Disord. 2020;46:102451. https://doi.org/10.1016/j.msard.2020.102451.
Weiss D, Cantre D, Zettl UK, Storch A, Prudlo J. Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab. J Neurol. 2022;269(5):2778–80. https://doi.org/10.1007/s00415-021-10913-y.
Khimani K, Patel SP, Whyte A, Al-Zubidi N. Case report: Neuromyelitis Optica after treatment of uveal melanoma with Nivolumab and Ipilimumab. Front Oncol. 2022;12:806501. https://doi.org/10.3389/fonc.2022.806501.
Liu J, Mori M, Sugimoto K, Uzawa A, Masuda H, Uchida T, et al. Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. J Neurol Neurosurg Psychiatry. 2020;91(2):132–9. https://doi.org/10.1136/jnnp-2019-321988.
Iorio R, Rindi G, Erra C, Damato V, Ferilli M, Sabatelli M. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4. Mult Scler. 2015;21(6):791–4. https://doi.org/10.1177/1352458515572241.
Warth A, Muley T, Meister M, Herpel E, Pathil A, Hoffmann H, et al. Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer. 2011;11:161. https://doi.org/10.1186/1471-2407-11-161.
We thank Mr. Masahiro Nagata, Division of Laboratory Medicine, Funabashi Central Hospital, Chiba, Japan, and Ms. Yuriko Ogawa, Department of Neurology, National Hospital Organization Chiba-Higashi Hospital, Chiba, Japan, for support with immunohistochemical staining.
Authors and Affiliations
Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8670, Japan
Shigeki Hirano, Satoshi Kuwabara & Masahiro Mori
Department of Internal Medicine, Funabashi Central Hospital, Funabashi, Chiba, Japan
Shigeki Hirano & Akira Kojima
Department of Ophthalmology, Funabashi Central Hospital, Funabashi, Chiba, Japan
Department of Neurology, National Hospital Organization Chiba-Higashi Hospital, Chiba, Chiba, Japan
Department of Molecular Pathology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Yamagata, Japan
SH: Conceptualization, Data curation, Writing original draft, AK, YN: Data curation, TT, TK: Pathological investigation. TT: Serological investigation, SK: Supervision, Writing review, MM: Conceptualization, Serological investigation, Writing original draft. All authors read and approved the final manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Hirano, S., Kojima, A., Nakayama, Y. et al. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
BMC Neurol22, 483 (2022). https://doi.org/10.1186/s12883-022-02987-6